Glucocorticoid resistance in inflammatory diseases

PJ Barnes, IM Adcock - The Lancet, 2009 - thelancet.com
Glucocorticoid resistance or insensitivity is a major barrier to the treatment of several
common inflammatory diseases—including chronic obstructive pulmonary disease and …

The use of THP-1 cells as a model for mimicking the function and regulation of monocytes and macrophages in the vasculature

Z Qin - Atherosclerosis, 2012 - Elsevier
Since their establishment thirty years ago, THP-1 cells have become one of most widely
used cell lines to investigate the function and regulation of monocytes and macrophages in …

PAAN/MIF nuclease inhibition prevents neurodegeneration in Parkinson's disease

H Park, TI Kam, H Peng, SC Chou… - Cell, 2022 - cell.com
Parthanatos-associated apoptosis-inducing factor (AIF) nuclease (PAAN), also known as
macrophage migration inhibitor factor (MIF), is a member of the PD-D/E (X) K nucleases that …

A nuclease that mediates cell death induced by DNA damage and poly (ADP-ribose) polymerase-1

Y Wang, R An, GK Umanah, H Park, K Nambiar… - Science, 2016 - science.org
INTRODUCTION Poly (ADP-ribose)(PAR) polymerase-1 (PARP-1) is a nuclear enzyme
responding to oxidative stress and DNA damage. Excessive activation of PARP-1 causes an …

Host–pathogen interactions in sepsis

T van der Poll, SM Opal - The Lancet infectious diseases, 2008 - thelancet.com
Sepsis is a major health problem. The concept that sepsis mortality is the result of an
uncontrolled hyperinflammatory host response has recently been challenged. It is now …

Novel roles of peroxiredoxins in inflammation, cancer and innate immunity

T Ishii, E Warabi, T Yanagawa - Journal of clinical biochemistry and …, 2012 - jstage.jst.go.jp
抄録 Peroxiredoxins possess thioredoxin or glutathione peroxidase and chaperone-like
activities and thereby protect cells from oxidative insults. Recent studies, however, reveal …

MIF, a controversial cytokine: a review of structural features, challenges, and opportunities for drug development

J Bloom, S Sun, Y Al-Abed - Expert opinion on therapeutic targets, 2016 - Taylor & Francis
Introduction: Macrophage migration inhibitory factor (MIF) has emerged as a promising drug
target in diseases including sepsis, rheumatoid arthritis, and cancer. MIF has multiple …

Rediscovering MIF: new tricks for an old cytokine

J Harris, S VanPatten, NS Deen, Y Al-Abed… - Trends in …, 2019 - cell.com
Produced by many cell types, macrophage migration inhibitory factor (MIF) is a pleiotropic
cytokine with critical and supporting roles in many disease states and conditions. Its disease …

Acute lung injury induced by lipopolysaccharide is independent of complement activation

D Rittirsch, MA Flierl, DE Day, BA Nadeau… - The Journal of …, 2008 - journals.aai.org
Although acute lung injury (ALI) is an important problem in humans, its pathogenesis is
poorly understood. Airway instillation of bacterial LPS, a known complement activator …

Current concepts in glucocorticoid resistance

N Yang, DW Ray, LC Matthews - Steroids, 2012 - Elsevier
Glucocorticoids (GCs) are the most potent anti-inflammatory agents known. A major factor
limiting their clinical use is the wide variation in responsiveness to therapy. The high doses …